Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081588 · ClinicalTrials.gov registry record · Phase 2
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
A Phase 2 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 2
- Development phase
- 555
- Enrollment target
NCT00081588: Completed Phase 2 study, sponsored by Tibotec Pharmaceuticals, Ireland.
NCT00081588 is a Phase 2 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 555 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081588, a Phase 2 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 555 participants
- Enrollment target
Study Summary
The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect over time.
Interventions
- DRUG TMC114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00081588 record still lists
NCT00081588 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 1 intervention - of which TMC114 is the first listed.
NCT00081588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00081588 about?
NCT00081588 is a clinical study titled "An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.". The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect over time.
What is the current status of trial NCT00081588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 555 participants. The study started on 2003-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00081588?
The interventions under investigation include: TMC114 (DRUG).
Who is sponsoring clinical trial NCT00081588?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00081588's enrollment target sits among peer trials
555 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia